TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/1/2026

1. SPY
2. NVDA
3. AVAV
4. NKE
5. MU
6. DLR
7. EOSE
8. TSLA
9. VSH
10. AAPL

Go back to TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer
(NASDAQ: RNAZ) Delayed: 6.21 +0.97 (18.51%)
Previous Close $5.24    52 Week High $ 
Open $5.15    52 Week Low $ 
Day High $6.30    P/E N/A 
Day Low $4.97    EPS $ 
Volume 51,678